Fortunately, this deficiency in efferocytic clearance is treatable with recombinant TGF-β, which restored expression of MERTK and Gas6 to basal levels in multiple sclerosis patients [224,225,228,229]. The gene discussed is GAS6; the disease is multiple sclerosis.